PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 4, 2026Cell Reports Methods2 citationsOpen Access

A lightweight TcrLM model predicts T cell receptor and epitope binding specificity

View Full Paper
CYChenpeng YuXFXing FangSTShiye Tian

Key Points

  • The aim is to create a model that accurately predicts TCR-antigen binding specificity using a lightweight approach.
  • Developed a lightweight, masked language model called tcrLM.
  • Pretrained tcrLM on a large-scale TCR CDR3 sequence dataset.
  • Evaluated performance on hold-out and external test sets, including a COVID-19 peptide set.
  • Assessed correlation of predicted TCR-neoantigen binding scores with immunotherapy response.
  • tcrLM demonstrated competitive performance, effectively predicting TCR-antigen binding.
  • Showed robust zero-shot generalization for unseen peptides.
  • In a melanoma cohort, predicted binding scores correlated with actual immunotherapy responses and patient outcomes.

Abstract

Immune responses depend on specific interactions between T cell receptors (TCRs) and peptides presented by antigen-presenting cells (APCs). The vast diversity of the TCR repertoire makes accurate prediction of TCR-antigen binding specificity highly challenging. Here, we present a lightweight, masked language model, tcrLM, to address this problem. We pretrain tcrLM on a large-scale TCR CDR3 sequence dataset and use the pretrained encoder to extract informative features for pTCR binding prediction. tcrLM achieves competitive performance on hold-out and external test sets and shows comparatively robust zero-shot generalization relative to several baselines on a large, unseen-COVID-19 peptide set. The model effectively captures biochemical properties and positional preferences of amino acids within TCR sequences. In an exploratory melanoma cohort, the predicted TCR-neoantigen binding scores correlate with immunotherapy response and clinical outcomes. These results highlight the potential of tcrLM for advancing immunotherapy and personalized medicine.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yu et al. (2026) studied this question.

synapsesocial.com/papers/69d0a9c8659487ece0fa430bhttps://doi.org/10.1016/j.crmeth.2026.101378
Ask AI
Helpful
Bookmark
Share
View Full Paper